The use of tumor markers in testis cancer in the United States: A potential quality issue

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 2, 2008, Pages 153-157

  Gilbert, Scott M ^a   Daignault, Stephanie ^b   Weizer, Alon Z ^a   Wei, John T ^a   Hollenbeck, Brent K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Performance measures; Quality of care; Testis cancer; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CANCER REGISTRY; CANCER STAGING; DEMOGRAPHY; DOCUMENTATION; HEALTH CARE QUALITY; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REIMBURSEMENT; TESTIS CANCER; UNITED STATES;

ADULT; HUMANS; MALE; MIDDLE AGED; QUALITY OF HEALTH CARE; SEER PROGRAM; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 39649123725     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.12.018     Document Type: Article

References (18)

1. McGlynn E.A., Asch S.M., Adams J., et al. The quality of health care delivered to adults in the United States. N Engl J Med 348 (2003) 2635-2645
2. Institute of Medicine. Performance measurement: Accelerating improvement (2006), National Academies Press, Washington D.C
3. Centers for Medicare and Medicaid Services, Medicare Demonstrations, Medicare Care Management Performance Demonstration, Clinical Quality Measures. http://www.cms.hhs.gov/DemoProjectsEvalRpts/ Accessed March 7, 2006
4. Horwich A., Shipley J., and Huddart R. Testicular germ-cell cancer. Lancet 367 (2006) 754-765
5. Schmoll H.J., Souchon R., Krege S., et al. European consensus on the diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 (2004) 1377-1399
6. Dearnaley D.P., Huddart R.A., and Horwich A. Regular review: Managing testicular cancer. BMJ 322 (2006) 1583-1588
7. Vastag B. Testicular cancer seen as the "stalking horse" for other cancers. J Natl Cancer Inst 91 (1999) 1801-1803
8. Thomas G., Jones W., Van Oosterom A., et al. Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res 357 (1990) 285-294
9. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 48 (2002) 1151-1159
10. Stephenson A.J., Bosl G.J., Bajorin D.F., et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 174 (2005) 557-560
11. Bosl G.J., and Motzer R.J. Testicular germ-cell cancer. N Engl J Med 337 (1997) 242-254
12. Zon R.T., Nichols C., and Einhorn L.H. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 16 (1998) 1294-1297
13. Overview of the SEER Program, National Cancer Institute Surveillance, Epidemiology, and End Results program description. http://seer.cancer.gov/about Accessed February 16, 2006
14. Hankey B.F., Ries L.A., and Edwards B.K. The surveillance, epidemiology and end results program: A national resource. Cancer Epidemiol Biomarkers Prev 8 (1999) 1117-1121
15. National Cancer Institute Surveillance, Epidemiology and End Result Program, Information for Cancer Registrars, SEER Coding and Staging Manual 2004, Appendix C, Site-Specific Coding Modules, Part 3. http://seer.cancer.gov/manuals/2004Revision%201/SPM_AppendixC_Part3_r1.pdf Accessed February 16, 2006
16. American Joint Commission on Cancer (AJCC). AJCC cancer staging manual. 6th ed. (2002), Springer-Verlag, New York (NY)
17. National Comprehensive Cancer Network, Practice Guidelines in Oncology-v. 1.2006. Testicular cancer. www.nccn.org/professionals/physician_gls/PDF/testicular.pdf Accessed December 14, 2005
18. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15 (1997) 594-603